Now showing items 1-1 of 1
Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury
(Biomed Central, 2017-07-24)
Background: FTY720 (fingolimod, Gilenya (TM)) is an oral, blood-brain barrier (BBB)-passing drug approved as immunomodulatory treatment for relapsing-remitting form of the multiple sclerosis (MS). In addition, FTY720 exerts ...